Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC) - Moehler, MH; Dvorkin, M; Ozguroglu, M (JCO, 2020)
et al.